The Pipeline

See what’s going on in the clinical technology world

Canadian study revives controversy over mammography screening

May 19, 2014

Rachel Bauch, Service Line Strategy Advisor

The global debate over breast cancer screening for women between the ages of 40 and 59 was revived early this year, when data released from a Canadian study concluded that “annual mammography in women aged 40 to 59 does not reduce mortality from breast cancer beyond that of physical examination or usual care when adjuvant therapy for breast cancer is freely available.” 

The basis for this debate is in part due to the difficulty in detecting lesions in younger women with denser breast tissue.

Read more »

Are you marketing your imaging technology to the right people?

May 6, 2014

Caitlin Visek, Service Line Strategy Advisor

For many hospitals, diagnostic imaging gets lost in the shuffle when it comes to marketing

But with growing patient price sensitivity and steerage from insurers, hospitals have a greater incentive than ever to communicate the value of their services to the market effectively to drive ROI. 

Read more »

Three lessons from proton therapy providers you need to learn

April 21, 2014

Catherine Castillo, Service Line Strategy Advisor

If the experience of operating proton centers is any indication, you may need to adjust your expectations for your center’s capacity and throughput before making a decision to enter the market.

Based on reports from various institutions at this year’s National Proton Conference, young proton centers are experiencing unanticipated challenges in their first years of operation, including slow ramp-up periods, high rates of referrals for complex cases, and workflow inefficiencies. When combined, these challenges have reduced centers’ total potential capacity and consequently dampened their financial outlook. 

Read more »

Three big robotic surgery trends to watch this year

April 9, 2014

Vik Srinivasan, Service Line Strategy Advisor

Last week’s Daily Briefing reported that the United States’ Food and Drug Administration just approved the first new model of the da Vinci robot in five years. 

With this announcement, hospitals will likely face increased pressure from physicians to upgrade their robots to the latest model. As a result, we thought this would be a good opportunity to review the near-term outlook for robotic surgery. 

Read more »

ACC 2014: The future of aortic aneurysm care—PEVAR in the cath lab

April 3, 2014

Vanessa Lo, Service Line Strategy Advisor

During one scientific session on the future of vascular services, experts highlighted the potential for percutaneous endovascular abdominal aneurysm repair (PEVAR) to impact aortic aneurysm care.

Recently, PEVAR has gained interest among vascular surgeons as the fully percutaneous procedure utilizes a suture closure device and requires only local or general anesthesia. With a less invasive approach, PEVAR results in lower morbidity, shorter procedure time, and reduced operating room (OR) costs. These advantages suggest the potential for the procedure to be performed in the cath lab with local anesthesia rather than in the OR.

Read more »

ACC 2014: Radial PCI learning curve may be overstated

April 3, 2014

Jake Kahane, Service Line Strategy Advisor

This year’s ACC conference reviewed the latest in cardiovascular service advancement. Below we highlight one of four key takeaways for our coverage of this year’s scientific session.

Service Line Strategy Advisor has covered the major benefits radial access for endovascular procedures such as PCI can have on your program’s cost of care, length-of-stay (LOS), and readmissions. In the U.S., these clinical and financial benefits have helped radial access utilization for PCI procedures grow from 1.2% of cases in 2007 to 16.1% in the third quarter of 2013. Internationally, transradial utilization rates are even higher—benchmarked at more than 50% of PCI procedures in France, Scandinavian countries, the UK, Spain, and Italy.

Read more »

ACC 2014: Renal denervation results call for further investigation

April 3, 2014

Vanessa Lo, Service Line Strategy Advisor

This year’s American College of Cardiology (ACC) conference reviewed the latest in CV service advancements. Here we highlight one of the four key takeaways from our coverage of this year’s sessions.

Renal denervation was in the spotlight at the ACC conference. In January, Medtronic announced that their SYMPLICITY HTN-3 trial, which evaluated the safety and efficacy of renal denervation device in patients with treatment-resistant hypertension compared to a sham-control group, had failed to meet its primary efficacy endpoint for blood pressure reduction.

Read more »

ACC 2014: Promising future for TAVR’s efficacy and LOS

April 3, 2014

Jake Kahane, Service Line Strategy Advisor

This year’s ACC conference reviewed the latest in cardiovascular service advancement. Below we highlight one of four key takeaways for our coverage of this year’s scientific session.

The future of the TAVR technology and the device’s cost-effectiveness were topics of high importance at ACC this year. Here, we highlight the key takeaways from ACC’s late-breaking TAVR trials and sessions on how to make your TAVR program profitable.

Read more »